DualityBio Inc.

9606 · HKEX

Public Market Listing

9606HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for DualityBio Inc. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(5 total)
5Total Assets
0Approved
2Phase 3 / Filed
3Phase 1–2 / Early
4Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
Phase 3
B7-H3Antibody–drug conjugate
Non-Small Cell Lung CancerMetastatic Castration-Resistant Prostate Cancer
Phase 3
HER2Antibody–drug conjugate
Breast CancerEndometrial Cancer
HR+/HER2- Metastatic Breast Cancer, HER2-Positive Breast Cancer
Phase 2
TROP2Antibody–drug conjugate
Non-Small Cell Lung Cancer
Phase 1/2
EGFR / HER3 (ERBB3) dualAntibody–drug conjugate
Non-Small Cell Lung Cancer
Phase 1/2
HER3Antibody–drug conjugate
Non-Small Cell Lung Cancer

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (5)
August 2027 (2)
Trastuzumab pamirtecanPhase 1/2HER2-positive Advanced Solid Tumor
Est. primary completion 2027-08 · NCT05150691 · CT.gov ↗
What to watch
Sacituzumab drozuntecanPhase 1/2Advanced Solid Tumor
Est. primary completion 2027-08-13 · NCT05438329 · CT.gov ↗
What to watch
December 2027 (3)
Elfetabart drozuntecanPhase 1/2Advanced Solid Tumors
Est. primary completion 2027-12 · NCT05914116 · CT.gov ↗
What to watch
Trastuzumab pamirtecanPhase 3HER2-positive Breast Cancer
Est. primary completion 2027-12 · NCT06265428 · CT.gov ↗
What to watch
DB-1310Phase 1/2Advanced Solid Tumor
Est. primary completion 2027-12-30 · NCT05785741 · CT.gov ↗
What to watch
2028 (2)
March 2028 (1)
Trastuzumab pamirtecanPhase 3Endometrial Cancer
Est. primary completion 2028-03 · NCT06340568 · CT.gov ↗
What to watch
September 2028 (1)
Elfetabart drozuntecanPhase 1/2Advanced Lung Cancer
Est. primary completion 2028-09 · NCT06892548 · CT.gov ↗
What to watch
2029 (1)
August 2029 (1)
Trastuzumab pamirtecanPhase 1/2Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
Est. primary completion 2029-08 · NCT06827236 · CT.gov ↗
What to watch
2030 (2)
June 2030 (2)
AVZO-1418Phase 1/2Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers, Epithelial Tumor, Biliary Tract Cancer (BTC) …
Est. primary completion 2030-06 · NCT07038343 · CT.gov ↗
What to watch
Est. primary completion 2030-06-30 · NCT06953089 · CT.gov ↗
What to watch
2031 (1)
February 2031 (1)
Elfetabart drozuntecanPhase 3Metastatic Castration-resistant Prostate Cancer
Est. primary completion 2031-02 · NCT07365995 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 October 2026Topline resultTrastuzumab pamirtecanDYNASTY-Breast02 Phase 3 (NCT06018337) met its primary PFS endpoint vs chemotherapy; the companies call the benefit limited
DualityBio Inc. · Source ↗
9 April 2026Filing acceptedDB-1303NMPA accepts BLA for trastuzumab pamirtecan (DB-1303)
CN, NMPA · DualityBio · Source ↗

Financial reports

No financial reports recorded.